Adv Mater: e2108476. IF=30.849
Mol Cancer 21(1): 86. IF=27.401
Mol Cancer 21(1): 75. IF=27.401
J Extracell Vesicles 11(3): e12198. IF=25.841
J Extracell Vesicles 11(4): e12209. IF=25.841
J Extracell Vesicles 11(3): e12203. IF=25.841
Signal Transduct Target Ther 7(1): 78. IF=18.187
Signal Transduct Target Ther 7(1): 74. IF=18.187
Adv Sci(Weinh): e2105811. IF=16.806
Adv Sci (Weinh): e2105586. IF=16.806
Nanomicro Lett 14(1): 75. IF=16.419
Prog Lipid Res 86: 101159. IF=16.195
Nat Commun 13(1): 1453. IF=14.919
Bioact Mater 15: 343-354. IF=14.593
Bioact Mater 15: 272-287. IF=14.593
Bioact Mater 14: 169-181. IF=14.593
Bioact Mater 12: 185-197. IF=14.593
Small Methods 6(3):e2100763. IF=14.188
Small: e2107354. IF=13.281
Biomaterials 283: 121462. IF=12.479
Biomaterials 283: 121465. IF=12.479
Biomaterials 283: 121413. IF=12.479
Biomaterials 283: 121448. IF=12.479
Neuro Oncol. IF=12.3
Embo j: e109902. IF=11.598
Theranostics12(5): 2322-2334. IF=11.556
Cell Mol Immunol 19(2): 210-221. IF=11.53
ClinTransl Med 12(3): e773. IF=11.492
Mol Ther. IF=11.454
ActaPharm Sin B 12(2): 939-951. IF=11.413
Acta Pharm Sin B12(2): 907-923. IF=11.413
J Exp Clin Cancer Res 41(1): 111. IF=11.161
JExp Clin Cancer Res 41(1): 85. IF=11.161
J Nanobiotechnology 20(1): 165. IF=10.435
J Nanobiotechnology 20(1):147. IF=10.435
J Nanobiotechnology 20(1): 123. IF=10.435
J Nanobiotechnology 20(1): 122. IF=10.435
J Nanobiotechnology 20(1): 144. IF=10.435
JNanobiotechnology 20(1): 97. IF=10.435
J Nanobiotechnology 20(1):150. IF=10.435
JNanobiotechnology 20(1): 135. IF=10.435
J Nanobiotechnology 20(1): 110. IF=10.435
J Nanobiotechnology 20(1): 132.
J Nanobiotechnology 20(1): 164.
编辑:小果果,转载请注明出处:https://www.cells88.com/cells/gxb/11633.html
免责声明:本站所转载文章来源于其他平台,主要目的在于分享行业相关知识,传递当前最新资讯。图片、文章版权均属于原作者所有,如有侵权,请及时告知,我们会在24小时内删除相关信息。
说明:本站所发布的案例均摘录于文献,仅用于科普干细胞与再生医学相关知识,不作为医疗建议。